Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy.
- Author:
Way Seah LEE
1
;
Najib AZMI
;
Ruey Terng NG
;
Sik Yong ONG
;
Sasheela Sri La PONNAMPALAVANAR
;
Sanjiv MAHADEVA
;
Ida HILMI
Author Information
- Publication Type:Case Report
- Keywords: Elderly patients; Anti-tumor necrosis factor; Serious infections
- MeSH: Adult; Cholera; Diarrhea; Humans; Inflammatory Bowel Diseases*; Klebsiella; Meningitis; Necrosis*; Opportunistic Infections; Pneumonia; Sepsis; Tuberculosis
- From:Intestinal Research 2017;15(4):524-528
- CountryRepublic of Korea
- Language:English
- Abstract: Anti-tumor necrosis factor (anti-TNF) is highly effective in inflammatory bowel disease (IBD); however, it is associated with an increased risk of infections, particularly in older adults. We reviewed 349 patients with IBD, who were observed over a 12-month period, 74 of whom had received anti-TNF therapy (71 patients were aged <60 years and 3 were aged ≥60 years). All the 3 older patients developed serious infectious complications after receiving anti-TNFs, although all of them were also on concomitant immunosuppressive therapy. One patient developed disseminated tuberculosis, another patient developed cholera diarrhea followed by nosocomial pneumonia, while the third patient developed multiple opportunistic infections (Pneumocystis pneumonia, cryptococcal septicemia and meningitis, Klebsiella septicemia). All 3 patients died within 1 year from the onset of the infection(s). We recommend that anti-TNF, especially when combined with other immunosuppressive therapy, should be used with extreme caution in older adult patients with IBD.
